Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, HÃ¥kansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E
Parkinsonism Relat Disord. 2005 11 Suppl 1: S25-9

PMID: 15885624 · DOI:10.1016/j.parkreldis.2004.11.005

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa therapy for Parkinson's disease. Taking advantage of a monkey brain bank constituted to study the pathophysiology of levodopa-induced dyskinesia, we here report the changes affecting D1, D2 and D3 dopamine receptors within the striatum of four experimental groups of non-human primates: normal, parkinsonian, parkinsonian treated with levodopa without or with dyskinesia. We also report the possible role of arrestin and G protein-coupled receptor kinases.

MeSH Terms (8)

Antiparkinson Agents Dyskinesia, Drug-Induced Humans Levodopa Parkinson Disease Receptors, Dopamine D1 Receptors, Dopamine D2 Receptors, Dopamine D3

Connections (1)

This publication is referenced by other Labnodes entities: